{"id":12326,"date":"2026-01-21T14:07:38","date_gmt":"2026-01-21T09:07:38","guid":{"rendered":"https:\/\/ksestocks.com\/blog\/?p=12326"},"modified":"2026-01-21T14:07:40","modified_gmt":"2026-01-21T09:07:40","slug":"6-reasons-why-agp-could-rise-to-pkr-265-soon","status":"publish","type":"post","link":"https:\/\/ksestocks.com\/blog\/6-reasons-why-agp-could-rise-to-pkr-265-soon\/","title":{"rendered":"6 Reasons Why AGP Could Rise to PKR 265 Soon"},"content":{"rendered":"\n

AGP Limited (AGP<\/strong><\/a>) is showing clear company specific momentum that differentiates it from the broader pharmaceutical space. Its earnings growth, margin structure, and product mix provide a strong basis for revaluation. Based on the detailed AGP analysis in the 2026 strategy report, there are six concrete reasons supporting a move toward PKR 265.<\/p>\n\n\n\n

1: AGP Has the Highest Gross Margins in the Listed Pharma Space<\/h2>\n\n\n\n

Margins Are Well Above Industry Levels<\/h3>\n\n\n\n

AGP reported a gross margin of 58.3 percent in 9MCY25<\/strong>, the highest among listed pharmaceutical companies. The industry average remains close to 40 percent.<\/p>\n\n\n\n

This margin advantage is driven by strong brands, favorable pricing power, and operational efficiencies rather than one off factors.<\/p>\n\n\n\n

Margin Sustainability Is High<\/h3>\n\n\n\n

Management expects gross margins to remain near 60 percent<\/strong> going forward. Further stability is expected as consolidated operations mature.<\/p>\n\n\n\n

Gross Margin Comparison<\/strong><\/h4>\n\n\n\n
Category<\/strong><\/th>Gross Margin<\/strong><\/th><\/tr><\/thead>
AGP<\/td>58 to 60 percent<\/td><\/tr>
Industry Average<\/td>Around 40 percent<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n\n\n\n\n

2: AGP Is Gaining Market Share Through Volume Growth<\/h2>\n\n\n\n

Volumes Are Growing Despite Industry Stagnation<\/h3>\n\n\n\n

AGP has continued to grow volumes while the overall pharmaceutical industry has struggled.<\/p>\n\n\n\n

Key indicators show:<\/p>\n\n\n\n

    \n
  • AGP revenue growth in 9MCY25 of 15 percent year on year<\/strong>
    <\/strong><\/li>\n\n\n\n
  • Expected CY25 revenue growth of 17 percent<\/strong>
    <\/strong><\/li>\n\n\n\n
  • AGP volume growth of 3.9 percent<\/strong>
    <\/strong><\/li>\n\n\n\n
  • Industry volume growth of minus 0.1 percent<\/strong>
    <\/strong><\/li>\n<\/ul>\n\n\n\n

    This points to market share gains rather than price driven growth.<\/p>\n\n\n\n

    Core Brands Are Driving Demand<\/h3>\n\n\n\n

    AGP\u2019s portfolio includes well established brands such as Azomax, Rigix, Norvasc, Osnate D, and Anafortan Plus. These brands support consistent prescriptions and repeat demand.<\/p>\n\n\n\n\n\n\n\n

    3: Product Mix Is Tilted Toward Higher Margin Non Essential Drugs<\/h2>\n\n\n\n

    Non Essential Exposure Is Among the Highest in the Sector<\/h3>\n\n\n\n

    AGP has a significant exposure to non essential drugs which allow better margin control.<\/p>\n\n\n\n

      \n
    • Consolidated non essential mix stands at 66 percent<\/strong>
      <\/strong><\/li>\n\n\n\n
    • Standalone non essential mix is 93 percent<\/strong>
      <\/strong><\/li>\n<\/ul>\n\n\n\n

      This mix reduces regulatory pricing pressure and supports profitability.<\/p>\n\n\n\n

      Pricing Pressure Has Largely Passed<\/h3>\n\n\n\n

      Most price adjustments were already taken in CY25. Going forward, growth is expected to come increasingly from volumes rather than price hikes.<\/p>\n\n\n\n\n\n\n\n

      4: OBS Acquisition Has Shifted AGP Toward Chronic Therapies<\/h2>\n\n\n\n

      Chronic Segment Share Has Increased Sharply<\/h3>\n\n\n\n

      Following the acquisition of OBS Pakistan, AGP\u2019s exposure to chronic therapies has expanded meaningfully.<\/p>\n\n\n\n

        \n
      • Chronic share before acquisition was 2 to 3 percent<\/strong>
        <\/strong><\/li>\n\n\n\n
      • Chronic share after acquisition is around 19 percent<\/strong>
        <\/strong><\/li>\n<\/ul>\n\n\n\n

        Chronic therapies typically provide stable and recurring revenue streams.<\/p>\n\n\n\n

        Earnings Visibility Has Improved<\/h3>\n\n\n\n

        Patients using chronic medicines tend to remain on treatment longer. This improves predictability of sales and margins over time.<\/p>\n\n\n\n\n\n\n\n

        5: Export Business Is Creating Additional Growth Avenues<\/h2>\n\n\n\n

        Multiple Export Markets Are Now Active<\/h3>\n\n\n\n

        AGP currently exports to Afghanistan, Cambodia, Sri Lanka, and Kenya. New export markets are expected to be added over the next two years, with regulatory approvals in progress.<\/p>\n\n\n\n

        Afghanistan Exposure Remains Manageable<\/h3>\n\n\n\n

        Despite geopolitical concerns, AGP has already met its CY25 export target for Afghanistan. Long term risk remains limited due to Afghanistan\u2019s dependence on pharmaceutical imports from Pakistan.<\/p>\n\n\n\n\n\n\n\n

        6: Declining Finance Costs Will Lift Net Profitability<\/h2>\n\n\n\n

        Leverage Is Turning Into an Earnings Tailwind<\/h3>\n\n\n\n

        AGP carries relatively high leverage, but this is now working in its favor as interest rates decline.<\/p>\n\n\n\n

        As of September 2025:<\/p>\n\n\n\n

          \n
        • Debt to equity stood at 0.75 times<\/strong>
          <\/strong><\/li>\n\n\n\n
        • Debt to assets stood at 0.33 times<\/strong>
          <\/strong><\/li>\n<\/ul>\n\n\n\n

          The company is gradually retiring long term borrowings.<\/p>\n\n\n\n

          Net Margins Are Expected to Expand<\/h3>\n\n\n\n

          Net margins are expected to improve by up to 17 percent over the next three years<\/strong>, driven primarily by lower finance costs.<\/p>\n\n\n\n

          Earnings Outlook<\/h4>\n\n\n\n
          Metric<\/strong><\/th>CY25E<\/strong><\/th>CY26F<\/strong><\/th>CY27F<\/strong><\/th><\/tr><\/thead>
          Sales Rs mn<\/td>28,820<\/td>33,558<\/td>37,772<\/td><\/tr>
          PAT Rs mn<\/td>3,943<\/td>4,826<\/td>5,742<\/td><\/tr>
          EPS Rs<\/td>14.08<\/td>17.24<\/td>20.51<\/td><\/tr>
          DPS Rs<\/td>6.00<\/td>7.25<\/td>8.50<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          Valuation Supports Further Upside<\/strong><\/h2>\n\n\n\n

          AGP is trading at an estimated CY26 price to earnings multiple of around 11.8 times<\/strong>. Given its superior margins, volume driven growth, and improving profitability, this valuation leaves room for re rating.<\/p>\n\n\n\n

          At PKR 265, the stock also offers a dividend yield of approximately 4 percent<\/strong>.<\/p>\n\n\n\n

          What Are Analysts Saying About AGP Stock?<\/strong><\/h2>\n\n\n\n

          According to the KSEStocks Database, AGP is covered by 7 analysts in Pakistan and they have an average price rating of PKR 268. This average price target suggests an upside of 18.3% from the last close of PKR 226.99.<\/p>\n\n\n\n

          According to EPS estimates from 7 different brokers, AGP has an average 2026 EPS expectation of 16.7. This suggests the stock is now trading at a forward PE of 13.7.<\/p>\n\n\n\n

          Here is how the current AGP EPS estimates look like:<\/p>\n\n\n\n

          Symbol<\/strong><\/td>Research<\/strong><\/td>2024<\/strong><\/td>2025<\/strong><\/td>2026<\/strong><\/td>2027<\/strong><\/td>2028<\/strong><\/td>2029<\/strong><\/td>2030<\/strong><\/td>Last Updated<\/strong><\/td>Fwd P\/E 2026<\/strong><\/td>Fwd P\/E 2027<\/strong><\/td>Fwd P\/E 2028<\/strong><\/td>Fwd P\/E 2029<\/strong><\/td>Fwd P\/E 2030<\/strong><\/td>Last Close<\/strong><\/td><\/tr>
          AGP<\/strong><\/td>IGI<\/td><\/td>11.8<\/td>15<\/td>19.3<\/td><\/td><\/td><\/td>15\/12\/2025<\/td>15.1<\/td>11.8<\/td><\/td><\/td><\/td>226.99<\/td><\/tr>
          AGP<\/strong><\/td>Intermarket<\/td><\/td><\/td>16.64<\/td>19.63<\/td><\/td><\/td><\/td>01\/01\/2026<\/td>13.6<\/td>11.6<\/td><\/td><\/td><\/td>226.99<\/td><\/tr>
          AGP<\/strong><\/td>JS<\/td><\/td>14.08<\/td>17.24<\/td>20.51<\/td><\/td><\/td><\/td>01\/01\/2026<\/td>13.2<\/td>11.1<\/td><\/td><\/td><\/td>226.99<\/td><\/tr>
          AGP<\/strong><\/td>MMK<\/td>10.57<\/td>14.06<\/td>17.37<\/td>23.21<\/td><\/td><\/td><\/td>15\/01\/2026<\/td>13.1<\/td>9.8<\/td><\/td><\/td><\/td>226.99<\/td><\/tr>
          AGP<\/strong><\/td>Optimus<\/td><\/td>13.5<\/td>15.9<\/td>18.2<\/td><\/td><\/td><\/td>01\/01\/2026<\/td>14.3<\/td>12.5<\/td><\/td><\/td><\/td>226.99<\/td><\/tr>
          AGP<\/strong><\/td>Spectrum<\/td>9.53<\/td>12<\/td>14.6<\/td><\/td><\/td><\/td><\/td>01\/01\/2026<\/td>15.5<\/td><\/td><\/td><\/td><\/td>226.99<\/td><\/tr>
          AGP<\/strong><\/td>Taurus<\/td><\/td>14.3<\/td>19.9<\/td>23.2<\/td><\/td><\/td><\/td>01\/12\/2025<\/td>11.4<\/td>9.8<\/td><\/td><\/td><\/td>226.99<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          Here is how the current AGP Dividend estimates look like:<\/p>\n\n\n\n

          Symbol<\/strong><\/td>Research<\/strong><\/td>2024<\/strong><\/td>2025<\/strong><\/td>2026<\/strong><\/td>2027<\/strong><\/td>2028<\/strong><\/td>2029<\/strong><\/td>2030<\/strong><\/td>Last Updated<\/strong><\/td>Fwd Div Yield 2026<\/strong><\/td>Fwd Div Yield 2027<\/strong><\/td>Fwd Div Yield 2028<\/strong><\/td>Fwd Div Yield 2029<\/strong><\/td>Fwd Div Yield 2030<\/strong><\/td>Last Close<\/strong><\/td><\/tr>
          AGP<\/strong><\/td>IGI<\/td><\/td>5.8<\/td>7.5<\/td>9.8<\/td><\/td><\/td><\/td>15\/12\/2025<\/td>3.3<\/td>4.3<\/td><\/td><\/td><\/td>226.99<\/td><\/tr>
          AGP<\/strong><\/td>Intermarket<\/td><\/td><\/td>5<\/td>6<\/td><\/td><\/td><\/td>01\/01\/2026<\/td>2.2<\/td>2.6<\/td><\/td><\/td><\/td>226.99<\/td><\/tr>
          AGP<\/strong><\/td>JS<\/td><\/td>6<\/td>7.25<\/td>8.75<\/td><\/td><\/td><\/td>01\/01\/2026<\/td>3.2<\/td>3.9<\/td><\/td><\/td><\/td>226.99<\/td><\/tr>
          AGP<\/strong><\/td>MMK<\/td>4<\/td>5.63<\/td>6.95<\/td>9.28<\/td><\/td><\/td><\/td>15\/01\/2026<\/td>3.1<\/td>4.1<\/td><\/td><\/td><\/td>226.99<\/td><\/tr>
          AGP<\/strong><\/td>Optimus<\/td><\/td>6<\/td>7<\/td>8<\/td><\/td><\/td><\/td>01\/01\/2026<\/td>3.1<\/td>3.5<\/td><\/td><\/td><\/td>226.99<\/td><\/tr>
          AGP<\/strong><\/td>Spectrum<\/td>4<\/td>4<\/td>4<\/td><\/td><\/td><\/td><\/td>01\/01\/2026<\/td>1.8<\/td><\/td><\/td><\/td><\/td>226.99<\/td><\/tr>
          AGP<\/strong><\/td>Taurus<\/td><\/td>5<\/td>8<\/td>9<\/td><\/td><\/td><\/td>01\/12\/2025<\/td>3.5<\/td>4.0<\/td><\/td><\/td><\/td>226.99<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          Why do we compile research firms’ forecasts? Broker research is fragmented across different houses. Compiling it in one place helps investors see consensus, identify divergence, and think independently rather than relying on a single view.<\/p>\n\n\n\n

          Conclusion<\/strong><\/h2>\n\n\n\n

          AGP\u2019s investment case is built on execution and structural improvements within the business.<\/p>\n\n\n\n

          Strong margins, rising volumes, a favorable product mix, growing exposure to chronic therapies, expanding exports, and falling finance costs together create a clear pathway for earnings growth. These company specific factors support the case for AGP moving toward PKR 265<\/strong> in the near term.<\/p>\n","protected":false},"excerpt":{"rendered":"

          AGP Limited is showing clear company specific momentum that differentiates it from the broader pharmaceutical space. Its earnings growth, margin structure, and product mix provide a strong basis for revaluation. Based on the detailed AGP analysis in the 2026 strategy report, there are six concrete reasons supporting a move toward PKR 265.<\/p>\n","protected":false},"author":9253,"featured_media":6468,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[200],"class_list":["post-12326","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-psx-blog","tag-agp"],"featured_image_src":{"landsacpe":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/AGP-STOCK-PSX-1140x445.png",1140,445,true],"list":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/AGP-STOCK-PSX-463x348.png",463,348,true],"medium":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/AGP-STOCK-PSX-300x188.png",300,188,true],"full":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/AGP-STOCK-PSX.png",1920,1200,false]},"_links":{"self":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts\/12326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/users\/9253"}],"replies":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/comments?post=12326"}],"version-history":[{"count":4,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts\/12326\/revisions"}],"predecessor-version":[{"id":12333,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts\/12326\/revisions\/12333"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/media\/6468"}],"wp:attachment":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/media?parent=12326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/categories?post=12326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/tags?post=12326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}